Jiangzhong pharmaceutical: it is estimated that the total operating revenue in the first quarter of 2022 will be about 890 million yuan, with a year-on-year increase of about 30%

Survival Rules for Turbulent Times: A Compilation of the 20 Most Unmissable Core Insights from the 2026 Tsinghua PBCSF Forum

A dialogue between Zhu Min, former Deputy Governor of the People's Bank of China and former Vice Managing Director of the International Monetary Fund; Michael Spence, 2001 Nobel Prize winner in Economics and Philip H. Knight Professor Emeritus of Management at Stanford Graduate School of Business; and Masaaki Shirakawa, former Governor of the Bank of Japan, at the 2026 Tsinghua PBCSF Global Finance Forum.

Unpacking China | Key Chinese Firms to Watch This Week （20/09/2026-26/09/2026）

Amid fast-paced changes that fill the business community with excitement, angst and trepidation, EqualOcean will publish a series of roundup articles to document the major events related to Chinese companies going global every week.

Beyond the Car: China’s Next Wave of Intelligent Hardware

The next chapter for intelligent vehicles is unfolding both inside and beyond the car.

Moonshot AI’s Kimi K3 Joins Amazon Bedrock as Overseas Revenue-Sharing Model Takes Shape

Amazon Web Services announced on September 18 that Kimi K3, developed by China’s Moonshot AI（月之暗面）, is available on Amazon Bedrock, expanding the model’s access to enterprise customers through AWS’s managed AI platform. On September 21, National Business Daily reported that Moonshot had confirmed an overseas cloud revenue-sharing arrangement, adding a commercial dimension to the launch. The financial terms remain undisclosed.

CTTQ, Ampsourcebio Ink Agreement on Cure for NASH, T2DM

There are more than 95 plus major players and more than 90 plus nonalcoholic steatohepatitis (NASH) pipeline therapies, but none of them has been approved for marketing. Who would survive the competition in the blue-ocean market for NASH?